Altuviiio logo

Menu

expand_more

Mechanism of half-life extension (MOE)


Achieving high sustained mean Factor VIII levels (>40%) for most of the week in adults by overcoming the half-life limitations of von Willebrand Factor (vWF)1-3

___moeCard1.14054208175096629830.png

THE HALF-LIFE OF FACTOR VIII IS EXTENDED WITH NATURAL AMINO ACIDS1-4*

img_factor_viii.png

FACTOR VIII1,3,4

At the core of ALTUVIIIO is rFVIII, which replaces deficient FVIII in patients with hemophilia A

img_MOE_Fc_domain.png

Fc DOMAIN1,3,4

Delays FVIII degradation, and helps FVIII stay in circulation by slowing the clearance rate

img_MOE_XTEN POLYPEPTIDE.png

XTEN POLYPEPTIDE INSERTION1,3,4

Shields the FVIII molecule from proteolytic degradation and reduces binding to clearance receptors

img_MOE_vWF DD3 DOMAIN4.png

vWF D’D3 DOMAIN4

Prevents binding of FVIII to endogenous vWF

ALTUVIIIO is uniquely designed to be independent of the vWF chaperone3,4

* ALTUVIIIO is composed of naturally occurring amino acids that are able to be broken down through regular protein degradation processes.4

Discover how ALTUVIIIO achieves higher sustained mean Factor VIII levels (>40%)1-3

In a Phase 3 study, ALTUVIIIO offered a 48.2-hour half life in adults—the longest of any Factor VIII replacement therapy4-15†

† Comparison of data from XTEND-1 with half-life data recorded in prescribing information of approved Factor VIII replacement therapies.

icon_stonks.png

Learn how ALTUVIIIO was studied

The XTEND-1 trial studied ALTUVIIIO in the prophylaxis, on-demand, and perioperative settings in adult and adolescent patients.

icon_arrow.png

How ALTUVIIIO works

Discover more about this high sustained factor therapy in adult and adolescent patients.

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information
Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, may occur with ALTUVIIIO. Allergic-type hypersensitivity reactions were not reported in the clinical trials. Advise patients to discontinue use of ALTUVIIIO if hypersensitivity symptoms occur and contact a physician and/or seek immediate emergency care.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

IndicationImportant Safety Information

AUC=area under the curve; FVIII=Factor VIII; IU=international unit; IV=intravenous; PK=pharmacokinetic; rFVIII=recombinant Factor VIII; SD=standard deviation.

References: 1. von Drygalski A, et al. N Engl J Med. 2023;388(4):310-318. 2. Chhabra ES, et al. Blood. 2020;135(17):1484-1496. 3. Konkle BA, et al. N Engl J Med. 2020;383(11):1018-1027. 4. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 5. Adynovate Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA. 6. Afstyla Prescribing Information. CSL Behring LLC. Kankakee, IL. 7. Eloctate Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA. 8. Esperoct Prescribing Information. Novo Nordisk Inc. Plainsboro, NJ. 9. Kovaltry Prescribing Information. Bayer HealthCare LLC. Whippany, NJ. 10. Novoeight Prescribing Information. Novo Nordisk Inc. Plainsboro, NJ. 11. Nuwiq Prescribing Information. Octapharma USA, Inc. Paramus, NJ. 12. Xyntha Prescribing Information. Wyeth Pharmaceuticals LLC. Philadelphia, PA. 13. Advate Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA. 14. Jivi Prescribing Information. Bayer Healthcare LLC. Whippany, NJ. 15. Recombinate Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc. Lexington, MA.

© 2024 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate.

MAT-US-2403558-v1.0-05/2024 Last Updated: May 2024